RPG Life Sciences Declares FY26 Results, Recommends ₹24 Dividend

RPG Life Sciences posted a consolidated profit of ₹115.17 crore for the fiscal year ended March 31, 2026. Revenue from operations stood at ₹707.52 crore for the same period.

Reader Takeaway: Strong profit jump & big dividend approved; revenue growth steady but peers may show faster expansion.

What just happened (today’s filing)

The company announced its audited financial results for the fiscal year ending March 31, 2026. RPG Life Sciences reported a consolidated profit for the period of ₹115.17 crore.

Its revenue from operations for FY26 was ₹707.52 crore. Total income reached ₹733.10 crore, with profit before tax at ₹154.20 crore.

In a significant shareholder return announcement, the Board of Directors recommended a final dividend of ₹24 per equity share (300% on a face value of ₹8).

The board also approved the appointment of Dr. Pratit Samdani as an Additional Non-Executive Independent Director for a five-year term, effective April 29, 2026.

Why this matters

The recommended dividend payout of ₹24 per share offers a direct return to shareholders, signalling confidence in the company's financial performance.

Dr. Samdani's appointment enhances the board's expertise and governance structure, crucial for strategic oversight and decision-making.

The backstory (grounded)

RPG Life Sciences, part of the RPG Enterprises group, is an integrated pharmaceutical company involved in APIs, domestic, and international formulations.

For FY25, the company reported revenue of ₹653.4 crore and Profit Before Tax (PBT) of ₹150.3 crore. In FY23, revenue was ₹645.1 crore with a net profit of ₹71.4 crore.

The company has a history of dividend payouts, including ₹10 per share for FY23 and ₹8 for FY22. A recent recommended dividend of ₹24 per share for FY22 was noted, with an ex-dividend date around June 27, 2025.

What changes now

Shareholders can anticipate a substantial dividend payout, subject to approval.

The board composition is strengthened with the addition of an experienced independent director.

Risks to watch

In 2013, the US Food and Drug Administration (FDA) issued a warning letter to RPG Life Sciences regarding violations of good manufacturing practices at its Ankleshwar and Navi Mumbai facilities. While this is an older event, it highlights potential past regulatory compliance challenges that investors may wish to monitor for any recurrence or ongoing implications.

Peer comparison

RPG Life Sciences operates within the competitive Indian pharmaceutical sector alongside major players like Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., and Cipla Ltd.. While these peers are significantly larger, RPG Life Sciences' robust profit growth and substantial dividend recommendation stand out in its recent financial disclosures.

Context metrics (time-bound)

• For the financial year ended March 31, 2025, RPG Life Sciences reported revenue of ₹653.4 crore and PBT of ₹150.3 crore.

What to track next

Shareholder approval for the recommended final dividend of ₹24 per equity share.

The formal commencement of Dr. Pratit Samdani's tenure as an Additional Non-Executive Independent Director.

Monitoring any further updates or announcements regarding the company's business segments or strategic initiatives.

Monitoring the company's adherence to manufacturing and regulatory standards.